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PolyendocrinopathyThe pathogenesis of autoimmunity was derived from a complex interaction of genetic and environmental fac-
tors. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare autosomal recessive dis-
ease caused by mutations in the autoimmune regulator (AIRE) gene. AIRE gene variants and, in particular,
heterozygous loss-of-function mutations were also discovered in organ-speciﬁc autoimmune disorders, pos-
sibly contributing to their etiopathogenesis. It was suggested that even predisposition to develop certain au-
toimmune conditions may be derived from AIRE gene polymorphisms including S278R and intronic IVS9+6
G>A. In this study we unravel the hypothesis on whether AIRE gene variants may predispose individuals to
associated autoimmune conditions in 41 Italian patients affected by non-APECED autoimmune polyendo-
crinopathies. We could not detect any heterozygous mutations of the AIRE gene. Although a trend of associa-
tion was observed, heterozygous polymorphisms S278R and IVS9+6 G>A were detected in patients without
statistically signiﬁcant prevalence than in controls. Their putative contribution to autoimmune polyendo-
crinopathies and their predictive value in clinical strategies of disease development could be unravelled by
analysing a larger sample of diseased patients and healthy individuals.
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Autoimmune diseases are a heterogeneous group of disorders
derived from a complex interaction of genetic and environmental fac-
tors [1,2]. Rare autoimmune conditions may also result from single
gene mutations as in the case of autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) (OMIM#240300) [3], an
autosomal recessive disease caused by mutations in the autoimmune
regulator (AIRE) gene [4].
It has been suggested that genetic variability in the AIRE locus and
in particular heterozygous loss-of-function mutations might favour
the development of certain organ-speciﬁc autoimmune disorders by
affecting the presentation of self-antigens in the thymus and border-
line tolerance [5,6]. Of note in parents of APECED patients harbouring
heterozygous AIRE mutations, immunological dysregulation was
detected in the peripheral blood demonstrated by elevated levels of
IgA and activated T lymphocytes [7].
Heterozygous AIRE mutations were already reported in patients
affected by organ-speciﬁc autoimmune disorders including c.1411
C>T (R471C) mutation (exon 12) in a patient with chronic hypopara-
thyroidism, transient diabetes insipidus, chronic thyroiditis and
evidence of circulating parietal cell antibodies (PCA) [8]. The novel
heterozygous IVS9+6 G>A DNA change was reported in a patient
with Sjőgren's syndrome, autoimmune thyroiditis and psoriasis [9].
The compound heterozygous state IVS9+6G>A/c.1411 C>T was
found in the DNA of a patient with adrenal failure and autoimmune
thyroiditis [9]. The novel heterozygous D312N AIRE mutation (exon
8) was described in one patient with chronic hypoparathyroidism,
autoimmune thyroiditis, serum NALP5 (NLRP5) (leucine-rich-repeat
protein 5) [10] and anti-IFNω (interferon ω) antibodies [11], known
to be additional diagnostic markers for APECED [8].
Regarding autoimmune liver diseases [12–14] variations R257X,
G305S, P398fsX448, R441C, and c.961C>G (p. Ser278Arg, S278R, exon
7) were detected. In particular the S278R polymorphism was consid-
ered a genetic marker predisposing to AIH Type 1 [15].
A case control study by Tazi-Ahnini et al. [16] found G961C (S278R)
and T1029C (V301A) variants in alopecia areata. The G961C allele was
signiﬁcantly associated with alopecia universalis (AU) [17,18]. This
was not conﬁrmed in a case–control sample of patients with alopecia
areata of Belgian–German origin, despite adequate power [19].
Mutations V301M (G9861A) and T441M (C12532T) were found
in patients affected by both with systemic sclerosis (SSc) and auto-
immune thyroiditis [20]. The S278R polymorphism was also found
although did not correlate to SSc, regardless of whether it was asso-
ciated with autoimmune thyroiditis or not. It was more frequent in
the DNA of healthy subjects than patients, supporting the view that
this has a protective effect against SSc and autoimmune thyroiditis.
Instead the intronic polymorphism G11107A (IVS9+6 G>A)
strongly correlated with the association of SSc and thyroiditis,
suggesting that it could predispose to developing SSc-associated
thyroiditis.
In a Japanese GWA (genome wide association) study [21] two
intronic SNPs, rs2075876 and rs760426 were identiﬁed within the
AIRE gene. S278R (rs1800250) was in strong linkage disequilibrium
with rs2075876 compared with the alternative allele. No correlation
was observed between the rs2075876 genotype and quantitative
traits reﬂecting the progression of RA. Japanese authors could not con-
clude whether these SNPs have functional impact to the regulation of
AIRE expression.Other authors reported studies disproving associations between
variations in AIRE and autoimmune diseases. In the United Kingdom
population, the common APS1 mutation 964del13 did not show a sig-
niﬁcant association with autoimmune Addison's disease and autoim-
mune polyglandular syndrome Type 2 [22]. This did not also reveal
to be a susceptibility locus for the more common autoimmune endo-
crinopathies in the UK including Graves' disease, autoimmune hypo-
thyroidism and T1D [23].
A study population of 134 patients with Crohn's disease, 100 pa-
tients with ulcerative colitis and 145 healthy unrelated blood donors
of Caucasian origin sought to correlate the presence of AIRE gene mu-
tations in exons 6 and 8 with detectable circulating autoantibodies
[24]. Among three variations investigated (R257X mutation in exon
6, a 13-bp deletion and a 4-bp insertion in exon 8), none had signiﬁ-
cant association with circulating autoantibodies in inﬂammatory
bowel disease.
In Finnish type 1 diabetic patients ﬁve genotyped single nucleotide
polymorphisms (SNPs) of the AIRE gene were identiﬁed. Nevertheless
these did not show evidence of association with the disease [25].
In this report we unravel the hypothesis on whether the presence
of AIRE gene variations may predispose to associated autoimmune
conditions in a cohort of 41 Italian patients affected by non-APECED
polyendocrine syndromes.
2. Results and discussion
2.1. Clinical phenotype
2.1.1. Patients with autoimmune polyendocrinopathies and controls
This group included 41 patients, 29 females and 12 males, age
ranges between 6 and 29 years old. They were affected by autoim-
mune polyendocrinopathy types II [26], III [27] and IV [28,29]
(Table 1). A control group included 44 females and 40 males
(mean age 25 years).
2.2. Analysis of AIRE gene variants
2.2.1. Detection of IVS9+6 G>A intronic polymorphism
Analysis of the AIRE gene revealed the presence of the heterozy-
gous intronic polymorphism IVS9+6 G>A in 14 out of 41 patients
with autoimmune polyendocrinopathies. The DNA of 79 controls
was tested for the polymorphism. 22 out of 79 controls tested positive
(Tables 1, 2). Remarkably RT-PCR on patients' RNA demonstrated that
the polymorphism doesn't produce splicing effects on the translated
protein. Difference of prevalence between patients' group and con-
trols was not statistically signiﬁcant (Fig. 1A).
2.2.2. Detection of S278R polymorphism
S278R polymorphism was present in 7 out of 41 patients with
autoimmune polyendocrinopathies. The DNA of 84 controls was tested
for the polymorphism. 24 out of 84 controls tested positive (Tables 1, 2).
Difference of prevalence between patients' group and controls was not
statistically signiﬁcant (Fig. 1B).
2.3. Discussion
A complex interaction of genetic and environmental factors under-
lies the pathogenesis of autoimmune diseases [2]. Susceptibility genes
were reported to several autoimmune conditions, since they tend to
Table 1
Clinical and immunological characteristics of 41 patients affected by non-APECED autoimmunity.
Patients Gender Actual
age
Diseases Other diseases Polyendocrinopathy
type
Auto Abs
1 M 11 Alopecia, chronic gastritis Atopic dermatitis, onicodystrophy IV NT
2 F 8 Alopecia, HT Atopic dermatitis, onicodystrophy,
allergic rhinitis
IIIC ANA, anti-cardiolipin Abs, ASMA,
anti-thyroid Abs, IAA pos
ENA, GADA, anti-IA2 neg
3 M 12 T1D, HT, autoimmune
leukopenia
GH deﬁcit IIIA Anti-TPO, anti-TG Abs pos
Anti-TRG Abs neg
4 F 6 CD, HT IIIB ANA pos
5 F 12 HT, autoimmune hepatitis IIIB PCA pos
6 F 28 CD, autoimmune hepatitis IV Anti-TRG, anti-LKM Abs pos
7 F 22 HT, autoimmune hepatitis IIIB ANA, ANCA, ASMA pos
8 F 7 Alopecia, HT, CD III ANA, GADA, anti-TPO Abs pos
ANCA, IAA, anti-IA2, anti-TG,
anti-TRG Abs neg
9 F 11 T1D, Graves' disease, alopecia Nephrotic syndrome,
obesity
IIIC GADA, anti-IA2, anti-thyroid Abs pos
10 F 23 T1D, HT, vitiligo IIIA Anti-TPO Abs, ANA pos
GADA, anti-IA2, AMA, ASMA, PCA,
anti-TRG, anti-cardiolipin Abs neg
11 M 17 T1D, autoimmune
thrombocytopenia
IV Anti-TPO Abs, GADA pos
anti-platelets, anti-TG, anti-TRG Abs, ANA neg
12 F 22 Hyposurrenalism, HT,
autoimmune polyneuropathy
II ACA, ANA, ANCA, ASMA, anti-thyroid Abs pos
IAA, GADA, anti-IA2, AMA, anti-LKM,
PCA, anti-ribosome, anti-LC1, anti-TRG Abs neg
13 F 17 T1D, CD IV Anti-TPO Abs pos
anti-TRG Abs neg
14 F 19 T1D, CD, HT IIIA Anti-TPO Abs pos
anti-TG, anti-TRG Abs neg
15 F 22 T1D, HT IIIA Anti-thyroid Abs pos
anti-TRG Abs neg
16 F 20 T1D, HT IIIA Anti-IA2, GADA, anti-TPO Abs pos
anti-TG, anti-TRG Abs neg
17 M 23 T1D, CD IV GADA, anti-TRG Abs pos
IAA, anti-IA2 Abs neg
18 F 18 T1D, HT IIIA GADA, anti-TPO Abs pos
19 F 17 T1D, HT IIIA GADA, anti-thyroid Abs pos
20 F 20 T1D, HT IIIA Anti-thyroid Abs pos
GADA, anti-IA2, anti-TRG Abs neg
21 F 28 T1D, HT, CD IIIA GADA, anti-IA2, anti-TRG, anti-TG Abs pos
IAA neg
22 F 22 T1D, HT IIIA GADA, anti-thyroid Abs pos
IAA, anti-IA2 Abs neg
23 F 16 T1D, CD IV IAA pos
GADA, anti-IA2, ICA neg
24 F 15 T1D, HT IIIA Anti-TPO Abs pos
anti-TRG Abs neg
25 F 16 T1D, HT IIIA Anti-IA2, anti-TPO pos
GADA, anti-TG neg
26 F 17 T1D, HT IIIA Anti-IA2, anti-TPO pos
GADA, anti-TG neg
27 M 15 T1D IV Anti-TRG Abs pos
28 F 9 HT, autoimmune
hypoparathyroidism,
autoimmune hemolitic
anaemia
IIID ANA, IAA, anti-thyroid, anti-cardiolipin Abs pos
ENA, anti-phospholipids, anti-β2 glycoprotein 1,
anti-dsDNA, anti-IA2 Abs, GADA, ACA neg
29 F 12 HT, alopecia MC IIIC Anti-thyroid Abs pos
30 F 22 T1D, HT IIIA GADA, PCA, anti-TPO Abs pos
anti-IA2, anti-TG, anti-TRG Abs neg
31 M 23 HT IIID Anti-TPO Abs, anti-TRG Abs pos
anti-TG, anti-IA2 Abs, GADA neg
32 M 15 T1D, HT IIIA Anti-thyroid Abs pos
anti-TPO Abs, GADA, ACA neg
33 F 15 T1D, vitiligo IV ACA, anti-IA2 Abs, PCA pos
anti-thyroid, anti-TRG, anti-cardiolipin Abs,
GADA, ANA, ASMA, AMA neg
34 M 29 T1D, CD IV Anti-thyroid Abs pos
anti-TRG Abs neg
35 F 21 HT, CD IV Anti-thyroid Abs pos
anti-TRG Abs, GADA, anti-IA2, ACA neg
36 M 14 T1D, CD IV GADA, IAA, anti-thyroid Abs, PCA pos
ANA, AMA, ASMA, anti-intrinsic factor, anti-TRG,
anti-cardiolipin, anti-IA2 Abs, ACA neg
37 M 29 T1D, CD, HT IIIA Anti-TPO Abs pos
anti-TRG Abs neg
(continued on next page)
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Table 1 (continued)
Patients Gender Actual
age
Diseases Other diseases Polyendocrinopathy
type
Auto Abs
38 M 17 T1D, CD IV ANA, GADA, anti-IA2, anti-TPO Abs pos
anti-TG, anti-TRG Abs, PCA, AMA, ASMA, anti-LKM,
anti-reticulin, anti-ribosome, anti-cardiolipin,
anti-LC1 Abs neg
39 F 14 T1D, CD IIIA Anti-TPO Abs, GADA pos
anti-TG, anti-TRG, anti-IA2 Abs neg
40 F 27 T1D, HT IIIA GADA, anti-IA2 Abs pos
ACA, anti-TRG Abs neg
41* F 15 T1D, HT, AU, CD, MC Turner syndrome, psychomotor
retardation, intellectual disability,
sensorineural deﬁcit, facial
eczema, leg lipodystrophy, muscle
weakness and hypotrophy,
subclinical hyposurrenalism
IIIA GADA, ICA, ANA, anti-thyroid, anti-21OH Abs pos
GH = growth hormone; CD: celiac disease; HT: Hashimoto's thyroiditis; T1D insulin-dependent diabetes (Type 1 diabetes); AU: alopecia universalis; MC: mucocutaneous candi-
diasis. * reference [33].
ANA: antinuclear antibodies; ASMA: anti-smooth muscle antibodies; ANCA: anti-neutrophil cytoplasmic antibodies; AMA: anti-mitochondrial antibodies; dsDNA: double stranded
DNA; ICA: islet cell antibodies; IAA: anti-insulin autoantibodies; anti-IA2 Abs: anti protein tyrosine phosphatase insulinoma associated antigen 2 antibodies; anti-TPO Abs: anti
thyroperoxidase autoantibodies; anti-TG Abs: anti-thyroglobulin Abs; ENA: extractable nuclear antigens; GADA: anti-glutamic acid decarboxylase (isoform 65) autoantibodies;
ACA: adrenal cortex antibodies; anti-21OH hydroxylase autoantibodies (tested by radioimmunoassay with 125I-labelled 21OH by Professor C. Betterle, Padua University, Italy);
anti-thyroid [anti-Tg and anti-TPO]Abs; anti-LC1Abs: liver cytosol Type1 antibodies; anti-LKM: liver–kidneymicrosomal antibodies; anti-TRG (TGM)Abs: anti-transglutaminase antibodies;
PCA: parietal cell antibodies; NT: not tested.
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gene approaches have identiﬁed several gene variations in autoim-
mune thyroid disease, T1D and their association, namely autoimmune
polyglandular syndrome type 3 variant (APS3v) [30]. Among most
common susceptibility genes human leucocyte antigen (chromosome
2), cytotoxic T lymphocyte-associated antigen 4 (chromosome 6),
Fork head box P3 (X chromosome), the interleukin 2 receptor alpha/
CD25 gene region (chromosome 10) and PTPN22 (protein tyrosine
phosphatase, non receptor type 22, on chromosome 1) are encoun-
tered [31,32]. TNF-α gene on chromosome 6 has been reported to be
a susceptibility gene for patientswith both T1D and ATD in a European
sample [27].
It has been hypothesised that heterozygous mutations of the AIRE
gene, already reported in patients affected by organ-speciﬁc auto-
immune disorders [5,9], may exert a pathogenetic role in autoim-
mune conditions. In particular, the presence of polymorphisms
such as S278R and IVS9+6 G>Awas supposed to play a pathogenetic
role and was considered a genetic marker predisposing to someTable 2
Presence of genetic polymorphisms of the AIRE genes S278R and IVS9+6 G>A in 41 pa-
tients affected by autoimmune polyendocrine syndromes.
Patients AIRE gene pattern Patients AIRE gene pattern
1 Het. IVS9+6 G>A 22 Wild type
2 Het. IVS9+6 G>A 23 Wild type
3 Het. IVS9+6 G>A 24 Wild type
4 Het. IVS9+6 G>A 25 Wild type
5 Wild type 26 Het. IVS9+6 G>A/S278R
6 Het. S278R 27 Het. IVS9+6 G>A/S278R
7 Wild type 28 Het. IVS9+6 G>A/S278R
8 Wild type 29 Het.S278R
9 Wild type 30 Wild type
10 Het. IVS9+6 G>A/S278R 31 Wild type
11 wild type 32 Het. IVS9+6 G>A
12 wild type 33 Wild type
13 Wild type 34 Wild type
14 Wild type 35 Wild type
15 Wild type 36 Wild type
16 Wild type 37 Wild type
17 Het. IVS9+6 G>A 38 Het. IVS9+6 G>A
18 Wild type 39 Het. IVS9+6 G>A
19 Wild type 40 Het. IVS9+6 G>A
20 Wild type 41 Het. IVS9+6 G>A/S278R
21 Wild typeautoimmune disorders including alopecia. Nevertheless, contrasting
reports on the pathogenetic signiﬁcance of AIRE polymorphisms in
autoimmune thyroid disease and T1D [23], T1D [25] and inﬂamma-
tory bowel disease [24] were also reported.
We set out to test the hypothesis on whether heterozygous muta-
tion or polymorphisms of the AIRE gene could predispose individuals
to autoimmune polyendocrinopathies, thus unravelling their putative
utility in prediction strategies.
The results of the present investigation clearly indicate a trend of
association with autoimmune polyendocrinopathies of polymor-
phisms IVS9+6 G>A and S278R although a statistically signiﬁcant
prevalence in patients than in controls was not found, thus possibly
excluding their putative contribution to disease pathogenesis. In
case of the intronic variant even a putative linkage disequilibrium
with other predisposing haplotypes is excluded [20]. In addition
the intronic polymorphism doesn't produce a splicing effect on the
translated protein.
Failure of our study to ﬁnd a deﬁnitive association could be due to
insufﬁcient power or heterogeneity within the sample. It remains
however possible to speculate that, if a larger sample of patients
with autoimmune polyendocrinopathies and controls was to be
analysed, a statistically signiﬁcant association of the described poly-
morphisms might have been found.
3. Conclusions
In our study a trend of association between S278R and IVS9+6 G>A
polymorphisms in non-APECED autoimmune polyendocrinopathies
was observed although a statistically signiﬁcant prevalence in patients
than in controls was not found. Further studies based on extended
epidemiological investigations should clarify the functional signiﬁ-
cance of AIRE gene variations in autoimmune polyendocrinopathies,
therefore their putative clinical utility in prediction strategies of dis-
ease development.
4. Materials and methods
4.1. Subjects
Forty-one patients with autoimmune polyendocrinopathies were
recruited from the Endocrinology Unit at Bambino Gesù Children's
Hospital. As controls, 84 healthy blood donors were recruited from
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Fig. 1. Statistical analysis (X2 test) of differences in the prevalence of AIRE gene polymorphisms in patients with autoimmune polyendocrinopathies and controls. A. Prevalence of
the IVS9+6 G>A intronic polymorphism in polyendocrine patients and controls. No statistically signiﬁcant difference was observed. B. Prevalence of the S278R polymorphism in
polyendocrine patients and controls. No statistically signiﬁcant difference was observed.
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they had no history of autoimmunity and no autoantibodies were
detected in their serum. Informed consent was obtained from all
those who took part in the present study.
4.2. DNA isolation and AIRE gene sequencing
Molecular analysis of the AIRE gene (GenBank ID: AJ009610) was
conducted by direct sequencing according to already published pro-
tocols [33,34].
To verifywhether intronic polymorphism IVS9+6G>Acould gener-
ate a splicing effect on the translated protein, RNA was extracted fromperipheral blood lymphocytes using RNeasy Mini Kit (Qiagen,
Hilden, Germany), retrotranscription was conducted using High ca-
pacity cDNA reverse transcription kit (Life technologies Ltd., Paisley,
UK) using random primers. A PCR product of 450 base pairs (bp) was
obtained on resulting cDNA using exon 9 forward primer 5′ GGG ACC
TGG AGG TGC TCC AGC TGC 3′ and exon 12 reverse primer 5′ GGG
TCA CGT CTC CTG AGC AGG ATC 3′ (annealing temperature 68.5 °C).
4.3. Statistical analysis
Differences in the number of subjects with the IVS9+6 G>A in-
tronic variation or the S278R polymorphism between patients and
168 A. Palma et al. / Genomics 102 (2013) 163–168controls were assessed by the X2 (chi square) test on variances
and the GraphPad Prism 5 (GraphPad Software, California, USA). A
P value less than 0.05 was considered signiﬁcant.
4.4. Detection of autoantibodies
Patients' sera were tested for Abs to thyroglobulin (TG) and
thyroperoxidase (TPO) by the chemiluminescence method; parietal
cells (PCA) and adrenal cortex (ACA) by indirect immunoﬂuorescence;
glutamic acid decarboxylase (isoform 65) (GADA), protein tyrosine
phosphatase IA2 (INSM2, insulinoma-associated antigen 2) by radioim-
munoassay (RIA).
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